Cancer center member participation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

June 2 - June 6, 2023

Members indicated in BOLD; Associated IU researchers, fellows and residents are underlined

Click the abstract titles for additional details

ORAL ABSTRACT SESSIONS

Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.

Oral abstract session | Abstract: 5006 | Session track: Genitourinary Cancer—Prostate, Testicular, and Penile

Authors: Lucia Nappi, Neetu Saxena, Sara Pautasso, Sylwia Mazurek, Guliz Ozgun, Catarina Kollmannsberger, Max Trottier Chi, Antoine Morin Coulombe, Maryam Soleimani, Kim N. Chi, Bernhard J. Eigl, Peter C. Black, Alan I. So, Martin Gleave, Sean Kern, Siamak Daneshmand, Nabil Adra, Lawrence H. Einhorn, Craig R. Nichols, Christian K. Kollmannsberger

Organizations: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, Vancouver Prostate Centre, Vancouver, BC, Canada, BC Cancer - Vancouver Centre, Vancouver, BC, Canada, BC Cancer, Vancouver, BC, Canada, Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada, BC Cancer, Vancouver Centre, Vancouver, BC, Canada, BC Cancer, Vancouver, BC, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada, Vancouver Prostate Center, University of British Columbia, Vancouver, BC, Canada, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada, University of British Columbia, Vancouver, BC, Canada, Uniformed Services University/Murtha Cancer Center, Bethesda, MD, University of Southern California, Los Angeles, CA, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Testicular Cancer Commons, Knoxville, TN, BC Cancer, Vancouver Cancer Center, Vancouver, BC, Canada

Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.

Oral abstract session | Abstract: 12003 | Session track: Symptoms and Survivorship

Authors: Meghna S. Trivedi, Joseph M. Unger, Dawn L. Hershman, Amy Darke, Daniel Louis Hertz, Thomas Brannagan, Stephanie Smith, Bryan P. Schneider, William Johnson Irvin,
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

Oral abstract session | Abstract: 8006 | Session track: Hematologic Malignancies


Organizations: The University of Texas MD Anderson Cancer Center, Houston, TX, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Icahn School of Medicine at Mount Sinai, New York, NY, Emory University School of Medicine, Atlanta, GA, University of Miami Health System, Miami, FL, Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, Karmanos Cancer Institute, Detroit, MI, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Columbia University Medical Center, New York, NY, Norton Cancer Institute, Louisville, KY, University of Michigan, Ann Arbor, MI, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).

Oral abstract session | Abstract: 10017 | Session track: Pediatric Oncology

Authors: Edoardo Pennesi, Erica Brivio, Marieke E Willemse, Yilin Jiang, Vincent HJ van der Velden, H Berna Beverloo, Chad Hudson, Nyla A Heerema, Luke Kuttschreuter, Jamie Frediani, Susan Spiller, Sandeep Batra, Michele Redell, Nicoletta Bertorello, Franco Locatelli, Inge M van der Sluis, Michael Roth, Nobuko Hijiya, C Michel Zwann

Organizations: Erasmus MC, Rotterdam, Netherlands, Prinses Maxima Centrum, Utrecht, Utrecht, Netherlands, Hematologics, Seattle, WA, Ohio State University in Columbus, Columbus, OH, Pfizer R&D UK Ltd, Sandwich, United Kingdom, CHOC Children's Hospital, Orange, CA, East Tennessee Children's Hospital, Knoxville, TN, Riley Hosp for Children, Indiana Univ, Indianapolis, IN, Baylor College of Medicine, Houston, TX, Regina Margherita Children's Hospital, S.C. Oncoematologia Pediatrica, Turin, Italy, IRCCS Bambino Gesù Children's Hospital, Sapienza University of Rome, Rome, Italy, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands, University of Texas MD Anderson Cancer Center, Houston, TX, Columbia University Medical Center, New York, NY
Incidence round screening performance among women with dense breasts undergoing abbreviated breast MRI and digital breast tomosynthesis (ECOG-ACRIN EA1141).

Oral abstract session | Abstract: 10502 | Session track: Prevention, Risk Reduction, and Hereditary Cancer

Authors: Christiane K. Kuhl, Constantine Gatsonis, Gillian Newstead, Bradley S Snyder, Na An, Ilana F. Gareen, Jennifer T Bergin, Habib Rahbar, Janice S. Sung, Jacobs Jacobs, Jennifer A Harvey, Mary H Nicholson, Robert C Ward, Jacqueline Holt, Andrew Prather, Kathy Miller, Mitchell D. Schnall, Christopher E Comstock

Organizations: Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany, Brown University School of Public Health, Providence, RI, University of Chicago Department of Family Medicine, Chicago, IL, Brown University, Providence, RI, UW Cancer Center at ProHealth Care, Waukesha, WI, University of Washington School of Medicine; Fred Hutch Cancer Center, Seattle, WA, Memorial Sloan Kettering Cancer Center, New York, NY, West Michigan Cancer Center, Kalamazoo, MI, University of Rochester, Rochester, NY, The Community Hospital, Munster, IN, Rhode Island Hospital, Providence, RI, Delaware/Christiana Care NCORP, Newark, DE, Gundersen Health System, Lacrosse, WI, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Hospital of the University of Pennsylvania, Philadelphia, PA

CLINICAL SCIENCE SYMPOSIUM

BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2-breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.

Clinical Science Symposium | Abstract: 1012 | Track: Breast Cancer

Authors: Amy Sanders Clark, Fengmin Zhao, Paula Klein, Alberto J. Montero, Carla Isadora Falkson, Elisa Krill-Jackson, Kendrith M. Rowland, Sagar D. Sardesai, Jason Anthony Incorvati, Patrick Michael Dillon, Antonio C. Wolff, Houra Loghmani, Richard Trauger, Thomas Charles Heineman, Matthew C. Coffey, Kathy Miller

Organizations: University of Pennsylvania, Philadelphia, PA, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA, Icahn School of Medicine at Mount Sinai, New York, NY, University Hospitals Seidman Cancer Center, Cleveland, OH, University of Rochester Medical Center Department of Medical Oncology, Rochester, NY, University of Miami Sylvester Cancer Center, Miami, FL, Carle Clinic, Champaign, IL, Ohio State University Comprehensive Cancer Center, Columbus, OH, Fox Chase Cancer Center, Temple University Health System, Doylestown, PA, University of Virginia, Charlottesville, VA, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, Oncolytics Biotech, San Diego, CA, Oncolytics Biotech, Calgary, AB, Canada, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

EDUCATION SESSIONS

Creating a Memorable Presentation Through the Integration of Learning Science

Education session | Track: Professional Development and Education Advances

Presentation 1: How to Make It Stick: Why Learning Science Is Transformative for Teaching

Presenter and panel moderator: Jennifer Schwartz
Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing

Education session | Track: Prevention, Risk Reduction, and Hereditary Cancer
Presentation 3: Is Tumor Sequencing Enough to Rule out Inherited Cancer Predisposition?
Presenter and panel moderator: Bryan P. Schneider

POSTER SESSIONS

The impact of physician gender on patient satisfaction in an academic hematology/oncology practice.
Poster session | Abstract: 11022, Poster: 475 | Track: Professional Development and Education Advances
Authors: Alaina Marie Turchi, Ahmed Bilal Khalid, Chi Mai Nguyen, Jing Su, Tarah Jean Ballinger, Shadia Ibrahim Jalal
Organizations: Indiana University, Indianapolis, IN, Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, Indiana University Simon Cancer Center, Indianapolis, IN

Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors.
Poster session | Abstract: 8598, Poster: 225 | Track: Lung Cancer
Authors: Fatemeh Ardeshir-Larijani, Karthik Raja Ravichandran, Bryan P. Schneider, Milan Radovich, Rohan Maniar, Ashiq Masood, Kenneth Kesler, Patrick J. Loehrer
Organizations: Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Dept of Cardiosurgery, Indianapolis, IN

Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).
Poster session | Abstract: 8565, Poster: 192 | Track: Lung Cancer
Authors: Cynthia Wei, Sandra K. Althouse, Hirva Mamdani, Nasser H. Hanna, Greg Andrew Durm
**Effect of colorectal cancer screening on 1-year mortality and medical costs: Real-world evidence from the largest commercial medical claims database in the US.**

Poster session | Abstract: 10579, Poster: 212 | Track: Prevention, Risk Reduction, and Hereditary Cancer

**Authors:** Chi Mai Nguyen, Jing Su

Organizations: Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN

---

**Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).**

Poster session | Abstract: TPS10068, Poster: 373a | Track: Pediatric Oncology

**Authors:** Emily Gustava Greengard, Melissa Bear, Bradley DeNardo, Noah Federman, Julie Krystal, Giselle Linda Saulnier Sholler, Yanhong Zhou, Holly Knoderer, Sarah C Nabinger, Lindsey M. Hoffman

Organizations: University of Minnesota, Eden Prairie, MN, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, The Warren Alpert Medical School of Brown University, Providence, RI, David Geffen School of Medicine UCLA, Los Angeles, CA, Cohen Children's Medical Center, New Hyde Park, NY, Levine Children's Hospital at Atrium Health, Charlotte, NC, Eli Lilly and Company, Indianapolis, IN, Eli Lilly and Company, Indianapolis, IN, Phoenix Children's Hospital, Phoenix, AZ

---

**Reduction in Curie score in neuroblastoma patients treated with naxitamab.**

Poster session | Abstract: 10042, Poster: 348 | Track: Pediatric Oncology

**Authors:** Jaume Mora, Godfrey Chi-Fung Chan, Daniel A. Morgenstern, Loredana Amoroso, Karsten Nysom, Joerg Faber, Arthur Wingerter, Melissa Bear, Alba Rubio-San-Simón, Brian H. Kushner, Karen Tornøe, Rene DePont Christensen

Organizations: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain, Hong Kong Children's Hospital, The University of Hong Kong, Hong Kong, Hong Kong, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, IRCCS Istituto Giannina Gaslini, Genoa, Italy, Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark, Center for Pediatric and Adolescent Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, Memorial Sloan Kettering Cancer Center, New York, NY, Y-mAbs Therapeutics, Inc., Hørsholm, Denmark, YmAbs A/S, Hørsholm, Denmark

---

**Multimodality, online oncology learning resources: Meeting residents where they are—A pilot to create a new oncology curriculum.**

5 | IU Simon Comprehensive Cancer Center members indicated in **BOLD**; Associated IU researchers, fellows and residents are *underlined*
**A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.**

**Poster session | Abstract: 4526, Poster: 18 | Track: Genitourinary Cancer—Kidney and Bladder**

**Authors:** Roberto Pili, Naomi B. Haas, Paul Monk, Theodore F. Logan, Vivek Narayan, Heather Burney, Nabil Adra

**Organizations:** University at Buffalo, Buffalo, NY, University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, Ohio State University, Columbus, OH, Indiana University, Indianapolis, IN, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

---

**Evaluating the impact of exercise in women living with indolent metastatic breast cancer: The EMBody trial.**

**Poster session | Abstract: TPS12140, Poster: 506b | Track: Symptoms and Survivorship**

**Authors:** Martha Cancilla, Donya Nemati, Danielle Halsey, Kelly Shanahan, Lesley Glenn, Keith Avin, Nicole Keith, Kathy Miller, Jennifer A. Ligibel, Tarah Jean Ballinger

**Organizations:** IU School of Medicine, Indianapolis, IN, IUPUI School of Health and Human Sciences, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN, METAvivor, South Lake Tahoe, CA, Project Life, Central Point, OR, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, Boston, MA, Indiana University Simon Cancer Center, Indianapolis, IN

---

**The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).**

**Poster session | Abstract: 12092, Poster: 460 | Track: Symptoms and Survivorship**


**Organizations:** University of Chicago, Chicago, IL, IU Simon Comprehensive Cancer Center, Indianapolis, IN, Memorial Sloan Kettering Cancer Center, New York, NY, University Health Network, Toronto, ON, Canada, University of Pennsylvania, Philadelphia, PA, University of Rochester School of Medicine & Dentistry, Rochester, NY, University of British Columbia, Vancouver, BC, Canada, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Dana-Farber Cancer Institute, Boston, MA, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Vanderbilt University, Nashville, TN, Indiana University Simon Cancer Center, Indianapolis, IN, Department of Medicine, University of Chicago, Chicago, IL
Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry.

Poster session | Abstract: 2038, Poster: 395 | Track: Central Nervous System Tumors

Authors: Ahmad Ozair, David Brachman, Lisa Campbell, Clark C Chen, Toral R. Patel, John Floyd, Devon H Hayden, Adam W Nowlan, Andrea C Wasilewski, John Wanebo, Mitesh Shah, Angela Richardson, Simon Hanft, Ondrej Choutka, Colette Shen, Zabi Wardak, Stuart Lee, Tulika Ranjan, Atulya Aman Khosla, Manmeet Singh Ahluwalia

Organizations: Miami Cancer Institute, Baptist Health South Florida, Miami, FL, GT Medical Technologies, Tempe, AZ, University of Minnesota Medical Center, Minneapolis, MN, University of Texas Southwestern Medical Center, Dallas, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX, BayCare Medical Center, Clearwater, FL, Piedmont Atlanta Hospital, Piedmont Healthcare, Atlanta, GA, Allina Healthcare, Minneapolis, MN, Barrow Neurological Institute, Phoenix, AZ, Indiana University School of Medicine, Indianapolis, IN, Westchester Medical Center, Valhalla, NY, Saint Alphonsus Spine Care, Boise, ID, University of North Carolina at Chapel Hill, Chapel Hill, NC, Vidant Health, Greenville, NC, Tampa General Hospital, Tampa, FL

SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.

Poster session | Abstract: TPS5103, Poster: 194b | Track: Genitourinary Cancer—Prostate, Testicular, and Penile

Authors: Antoine Morin Coulombe, Guliz Ozgun, Rebecca Johnson, Mark Andrew Lewis, Nabil Adra, Scott E. Eggener, Bruce J. Roth, Christopher W. Ryan, Christopher Porter, Fred Millard, Thomas Jang, Robert James Hamilton, Lawrence H. Einhorn, Christian K. Kollmannsberger, Kathryn B. Arnold, Charles David Blanke, Siamak Daneshmand, Craig R. Nichols, Lucia Nappi, Andrea Harzstark

Organizations: BCCancer, Vancouver, BC, Canada, Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada, Multicare, Tacoma, WA, Intermountain Healthcare, Murray, UT, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Center for Data Intensive Science at the University of Chicago, Chicago, IL, Washington University School of Medicine, St. Louis, MO, OHSU Knight Cancer Institute, Portland, OR, Virginia Mason Medical Center, Seattle, WA, UC San Diego Health, La Jolla, CA, Rutgers, New Brunswick, NJ, University Health Network, Toronto, ON, Canada, University of British Columbia, Vancouver, BC, Canada, SWOG Statistics and Data Management Center, Seattle, WA, SWOG Cancer Research Network Group Chair’s Office, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Testicular Cancer Commons, Knoxville, TN, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, Kaiser Permanente, San Francisco, CA

Identification of genes encoding targets associated with adverse events in multiple myeloma.

Poster session | Abstract: 1556, Poster: 150 | Track: Care Delivery and Regulatory Policy

Authors: Sherise C. Rogers, Ilyas Sahin, Jesus C. Fabregas, Ibrahim Nassour, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Omar Roger Kayaleh, Anita Ahmed Turk, Z. Hugh Fan, Karen Bullock Russell, David L. DeRemer, Carmen Joseph Allegra, Thomas J. George

Organizations: University of Florida/UF Health Cancer Center, Gainesville, FL, University of Florida Health Cancer Center, Gainesville, FL, Orlando Health, Orlando, FL, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, University of Florida, Gainesville, FL, Tallahassee Memorial HealthCare, Tallahassee, FL

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.


Organizations: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Kansas City, KS, NRG Oncology SDMC, and The University of Pittsburgh, Pittsburgh, PA, St. Luke’s University Health Network, Easton, PA, Orlando Health Cancer Institute, Orlando, FL, Ohio State University Comprehensive Cancer Center, Columbus, OH, UCLA Jonsson Comprehensive Cancer Center, UCLA Fielding School of Public Health, Los Angeles, CA, Emory University School of Medicine, Atlanta, GA, University of Pittsburgh, Pittsburgh, PA, Washington University School of Medicine, St. Louis, MO, CHU de Québec – Université Laval, Québec City, QC, Canada, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School and Alliance, New York, NY, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Mayo Clinic, Rochester, MN, Medical College of Wisconsin, Milwaukee, WI, The Allegheny Health Network Cancer Institute, Pittsburgh, PA, UPMC Hillman Cancer Institute.
Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.

Poster session | Abstract: 1059, Poster: 280 | Track: Breast Cancer

Authors: Lorenzo Gerratana, Yue Ren, Carolina Reduzzi, Meredith M. Regan, Reshma L. Mahtani, Cynthia X. Ma, Angela DeMichele, Jane Lowe Meisel, Kathy Miller, Trevor Augustus Jolly, Elizabeth Carlsson Riley, Rubina Qamar, Priyanka Sharma, Sonya A. Reid, Naomi Yu Ko, Yuan Liu, Harold J. Burstein, Sara M. Tolane, Massimo Cristofanilli, Erica L. Mayer

Organizations: CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy, Dana-Farber Cancer Institute, Boston, MA, Weill Cornell Medicine, New York, NY, Miami Cancer Institute, Baptist Health South Florida, Plantation, FL, Washington University School of Medicine, St. Louis, MO, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, Winship Cancer Institute of Emory University, Atlanta, GA, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of Louisville, Louisville, KY, Advocate Aurora Health, Milwaukee, WI, University of Kansas Cancer Center, Westwood, KS, Vanderbilt-Ingram Cancer Center, Nashville, TN, Boston University Section of Hematology and Medical Oncology, Boston, MA, Pfizer, Inc., La Jolla, CA

Phase Ila study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.

Poster session | Abstract: TPS1112, Poster: 322b | Track: Breast Cancer

Authors: Shipra Gandhi, Peter A. J. Forsyth, Mateusz Opyrchal, Kamran A. Ahmed, Kristopher Attwood, Ellis Glenn Levine, Tracey L. O'Connor, Amy P. Early, Robert Alan Fenstermaker, Dheerendra Prasad, Kazuaki Takabe, Brian J. Czerniecki, Pawel Kalinski

Organizations: Roswell Park Comprehensive Cancer Center, Buffalo, NY, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Indiana University School of Medicine, Indianapolis, IN, Roswell Park Cancer Institute, Buffalo, NY, Moffitt Cancer Center, Tampa, FL

A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.

Poster session | Abstract: 532, Poster: 362 | Track: Breast Cancer

Authors: Hyo S. Han, Robert Wesolowski, Carla Fisher, Shipra Gandhi, William R Gwin, Maria J Kowzun, Keerthi Gogineni, Hien Liu, Ricardo L Costa, Julian Guerrero, Stephy Mathew, Michael J. Schell, Hatem Hussein Soliman, Mary L. Disis, Brian J. Czerniecki

Organizations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Ohio State University Wexner Medical Center, Columbus, OH, Indiana University School of Medicine, Indianapolis, IN, Roswell Park Comprehensive Cancer Center, Buffalo, NY, University of Washington, Cancer Vaccine Institute, Seattle, WA
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.

Poster session | Abstract: TPS2677, Poster: 512a | Track: Developmental Therapeutics—Immunotherapy

Authors: Prantesh Jain, Alan Hutson, Cayla Janes, Debora S. Bruno, Greg Andrew Durm, Ashish Sangal, Bhoomi Mehrotra, Tania Crombet Ramos, Kalet Leon, Grace K. Dy

Organizations: Roswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Institute, Buffalo, NY, University Hospitals, Case Comprehensive Cancer Center, Cleveland, OH, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN, Catholic Health Systems, West Islip, NY, St. Francis Hospital, Greenvale, NY, Center of Molecular Immunology, Havana, Cuba

---

Patient perception and adherence to lung cancer screening in those who meet eligibility criteria.

Publication only | Abstract: e22503 | Track: Prevention, Risk Reduction, and Hereditary Cancer

Authors: Sasmith R. Menakuru, Vijaypal S. Dhillon, Amir F. Beirat, Nasser H. Hanna

Organizations: Indiana University School of Medicine, Muncie, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN

---

Bone metastasis in patients with germ-cell tumors: Analysis of survival outcomes and prognostic factors.

Publication only | Abstract: e17029 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile

Authors: Rebecca Hassoun, Jennifer King, Sandra K. Althouse, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra

Organizations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN

---

Trends of female representation in ASCO leadership and abstracts authorship: A detailed review.

Publication only | Abstract: e23010 | Track: Professional Development and Education Advances

Authors: Razan Aljaras, Ahmad Karkash, Vidya Sree Dandu, Ahmad Abdelfattah Alhader
Racial and ethnic differences in thymic epithelial tumors: A single-institution retrospective analysis.

Publication only | Abstract: e20649 | Track: Lung Cancer

**Authors:** Brice Wuthrich, Rohan Maniar, Emily Heldman, Louis Laniak, Hannah Davis, Fatemeh Ardesth-Larijani, Aaron John Spittler, Kenneth Kesler, Patrick J. Loehrer

Organizations: Indiana University School of Medicine, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

An evaluation of cisplatin, doxorubicin, and cyclophosphamide (PAC) compared to other regimens for patients with unresectable or metastatic thymic carcinoma: A single-institution retrospective analysis.

Publication only | Abstract: e20650 | Track: Lung Cancer

**Authors:** Brice Wuthrich, Rohan Maniar, Emily Heldman, Louis Laniak, Hannah Davis, Fatemeh Ardesth-Larijani, Aaron John Spittler, Kenneth Kesler, Patrick J. Loehrer

Organizations: Indiana University School of Medicine, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

Clostridium difficile infection and immune mediated diarrhea and colitis in patients with cancer on immune checkpoint inhibitors.

Publication only | Abstract: e14683 | Track: Developmental Therapeutics—Immunotherapy

**Authors:** Ahmed Bilal Khalid, Phillip Pham, Ashley Varga Maveddat, Geneva Mari Cunningham, Gerardo Calderon, Nasser H. Hanna

Organizations: Indiana University, Indianapolis, IN, Indiana University Internal Medicine, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN, Mayo Clinic Rochester, Rochester, MN, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN

Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.

Publication only | Abstract: e17044 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile

**Authors:** Rebecca Hassoun, Mark Tann, Justin Sims, Ashleigh Auxier, Sandra K. Althouse, Jennifer King, Nabil Adra

Organizations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN
Rates of colorectal cancer screening versus lung cancer screening: Where does the problem lie?

Publication only | Abstract: e22504 | Track: Prevention, Risk Reduction, and Hereditary Cancer

Authors: Sasmith R. Menakuru, Ahmed Salih, Vijaypal S. Dhillon, Nasser H. Hanna

Organizations: Indiana University School of Medicine, Muncie, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN

A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.

Publication only | Abstract: e15088 | Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Authors: Fadi Taza, Greg Andrew Durm, Mateusz Opyrchal, Shadia Ibrahim Jalal, Milan Radovich, Bryan P. Schneider, Anita Ahmed Turk

Organizations: Division of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN, Indiana University Simon Cancer Center, Indianapolis, IN, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

Clinical outcomes in patients with post-chemotherapy residual non-retroperitoneal (RP) disease in non-seminomatous germ-cell tumors (NSGCT).

Publication only | Abstract: e17027 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile

Authors: Jennifer King, Ryan Ashkar, Kenneth Kesler, Sandra K. Althouse, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra

Organizations: Indiana University, Indianapolis, IN, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN

The SMILE scale: A pilot study among patients with cancer.

Publication only | Abstract: e24036 | Track: Symptoms and Survivorship

Authors: Laura Vater, Ali Ajrouch, Patrick O. Monahan, Laura Jennewein, Yan Han, Ahmad Karkash, Nasser H. Hanna

Organizations: IU Simon Cancer Center, Indianapolis, IN, Indiana University School of Medicine Department of Medicine, Indianapolis, IN, Indiana University, Indianapolis, IN, Indiana University School of Medicine, Department of Medicine, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN
The association of demographic factors and disease stage on palliative care (PC) referral rates and completion of advanced directives in a lung cancer (LC) patient population.


Organizations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University School of Medicine Department of Medicine, Indianapolis, IN, IU Hematology/Oncology, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, OH, Indiana University School of Medicine- Muncie, Muncie, IN, Indiana University Simon Cancer Center, Indianapolis, IN

A randomized, open-label, phase II study of high-dose interleukin 2 vs high-dose interleukin 2 plus entinostat in renal cell carcinoma.

Authors: Roberto Pili, David I. Quinn, Ralph J. Hauke, Timothy Kuzel, Yan Han, Nabil Adra, Theodore F. Logan

Organizations: University at Buffalo, Buffalo, NY, USC Norris Comprehensive Cancer Center, Keck Medicine of USC, Los Angeles, CA, Nebraska Cancer Specialists - Midwest Cancer Center, Omaha, NE, Rush University Medical Center, Chicago, IL, Indiana University, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, IU Simon Comprehensive Cancer Center, Indianapolis, IN

A funder-based comparison of global oncology research led by NCI-designated cancer centers: Results from the 2021 Global Oncology Survey.

Authors: Elise M. Garton, Linsey Eldridge, Mishka K. Cira, Allison Frank, Patrick J. Loehrer, Kalina Duncan

Organizations: Center for Global Health, National Cancer Institute, National Institutes of Health, Rockville, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

Establishing clinical performance characteristics for Duoseq, a new assay for DNA and RNA sequencing.

Authors: Elizabeth Thacker, Magdalena Czader, Lin Wang, Eric Hsi, Christopher Giauque, Matthew Sperling, Andrea Vrydaghs, Jordan Bouldin, Robert Erno, Lanie Happ, Clay Parker, Sandeep Dave

Organizations: Data Driven Bioscience, Durham, NC, Indiana University, Indianapolis, IN, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University, Winston-Salem, NC, Indiana University Hospital, Indianapolis, IN, Duke University, Durham, NC

IU Simon Comprehensive Cancer Center members indicated in BOLD; Associated IU researchers, fellows and residents are underlined
Clinical outcomes with frontline immunotherapy (IO) in BRAF-mutant NSCLC.

Publication only | Abstract: e21089 | Track: Lung Cancer

Authors: Julian A. Marin-Acevedo, Ram Thapa, Sonam Puri, James Kevin Hicks, Jhanelle Elaine Gray

Organizations: Indiana University, Indianapolis, IN, Moffitt Cancer Center, Tampa, FL, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

TYPES OF PRESENTATIONS

The ASCO Scientific Program Committee chooses abstracts for the annual meeting and determines presentation format for each accepted abstract. The presentation types include:

Oral Abstract Sessions: This type of session includes 12-minute presentations of abstracts representing important clinical and translational research findings by topic category. Experts in the field are chosen to provide comprehensive 12-minute themed discussions of the findings from predetermined abstracts.

Clinical Science Symposia: Clinical Science Symposia provide foundational education on a specific topic combined with the presentation and discussion of relevant abstracts. Novel science is put into appropriate context, including assessment of applicability to clinical practice and the need for further research. Presenting authors give 12-minute oral presentations.

Poster Discussion Sessions: Each track-based poster discussion session is 90 minutes and highlights 12 abstracts from the poster session held earlier in the day. Four invited discussants each provide a 12-minute discussion placing the selected abstracts in context, with a focus on how the findings apply to clinical practice and future research.

Poster Sessions: Selected abstracts are grouped by topic and displayed on poster boards for 3 hours. The Poster Sessions include Trials in Progress abstracts within each track, designed to facilitate awareness of open, ongoing clinical trials of any phase.

Publication-Only Abstracts: Quality abstracts that are not selected by the ASCO Scientific Program Committee for presentation at the Annual Meeting may be chosen for inclusion online in the 2022 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology supplement.